Volume 43, Issue 1 | Clinical Drug Investigation

Search all Clinical Drug Investigation articles

Volume 43, Issue 1

January 2023

Filter by

Volume:

Sort by

Date published:

New to old Old to new

11 articles in this issue

Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis
Mengxia Gao
Lingqun Zhu
Fei Chen
Systematic Review 03 December 2022 Pages: 1 - 11
Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment
Xinyu Liu
Jian Shi
Fei Chen
Review Article 03 December 2022 Pages: 13 - 22
Part of 1 collection:

COVID-19 Articles Collection
Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial
Amy Legg
Niamh Meagher
Steven Y. C. Tong
Original Research Article Open access 10 October 2022 Pages: 23 - 33
Correction to: Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial
Amy Legg
Niamh Meagher
Steven Y. C. Tong
Correction Open access 19 November 2022 Pages: 35 - 35
Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women
Feng Shao
Yi Jiang
Daniël Martijn Jonker
Original Research Article Open access 07 December 2022 Pages: 37 - 44
Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis
Fernanda Ferreira Bomtempo
Rebeka Bustamante Rocha
João Paulo Mota Telles
Original Research Article 08 December 2022 Pages: 45 - 59
CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study)
Tanvi Patil
Emily Halsey
Davida Eppes
Original Research Article 14 December 2022 Pages: 61 - 74
Gastric Glitch: A New Functional Disease Treated with Buspirone and Prucalopride in an N-of-1 Double-Blind Clinical Trial
Gabriela Ambrós
Ricardo Valões
Fernando Fornari
Research Letter 12 November 2022 Pages: 75 - 78
Comment on “Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression”
Alina Wilkowska
Wiesław Jerzy Cubała
Letter to the Editor 16 November 2022 Pages: 79 - 80
Correction to: Comment on “Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression”
Alina Wilkowska
Wiesław Jerzy Cubała
Correction 02 December 2022 Pages: 81 - 81
Authors’ Response to Comment on “Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression”
Julia Diniz Grossi
Juliana Surjan
Acioly Luiz Tavares Lacerda
Letter to the Editor 25 November 2022 Pages: 83 - 84